GHK-Cu vs BPC-157
GHK-Cu has route-specific topical human evidence; BPC-157 evidence is overwhelmingly preclinical. Do not merge topical and injectable claims.
| Attribute | GHK-Cu | BPC-157 |
|---|---|---|
| Human evidence | Human evidence is route-specific and mixed. A randomized venous-ulcer study of topical 0.4% copper-tripeptide cream found no superiority over vehicle, and a 13-person randomized post-CO2-laser study found no significant objective skin benefit, although subjective satisfaction favored treatment. Injectable/systemic evidence remains much weaker. | Human evidence remains extremely limited. A 2025 systematic review found 35 preclinical studies and only one clinical study; a later retrospective real-world preprint cannot establish efficacy. GI and injury-healing claims remain dominated by animal/preclinical research. |
| Research focus | Skin, wound healing, collagen, hair/cosmetic research | Musculoskeletal injury, gastrointestinal and wound-healing research |
| Regulatory status | Injectable GHK-Cu is not an FDA-approved therapeutic product; FDA highlights compounded-injection safety uncertainty. | Not FDA-approved; FDA has highlighted safety-information gaps for compounded BPC-157. |
| Route / formulation | Topical cosmetic evidence cannot be automatically extrapolated to injected GHK-Cu. | Results from animal models cannot be presented as proven human healing effects. Research-grade product quality varies. |
Why these are compared
These compounds appear in the skin / tissue repair evidence landscape, but they are not interchangeable. GHK-Cu is copper-binding tripeptide complex studied in skin, wound healing, collagen, hair/cosmetic research; BPC-157 is synthetic 15-amino-acid peptide studied in musculoskeletal injury, gastrointestinal and wound-healing research. The purpose of this page is to compare the evidence base, not to recommend one compound over another.
Evidence maturity
GHK-Cu: Topical/cosmetic human evidence is limited and mixed; injectable evidence limited.
BPC-157: Primarily preclinical / extremely limited human evidence across injury and GI claims.
The table above gives the fuller human-evidence, regulatory and formulation context. Open the individual profiles for study-level records, limitations and source provenance.
What this comparison can and cannot establish
No head-to-head human trial identified. Cross-study comparisons can be distorted by differences in population, route, formulation, dose, duration and endpoint. WhichPeps therefore does not turn indirect comparisons into a treatment recommendation or name a winner. A well-designed head-to-head human trial using comparable populations and clinically relevant outcomes would reduce uncertainty.